Axcella Health IncOTC Pink - Limited Information:AXLA
- LAST PRICE0.9105
- TODAY'S CHANGE (%)0.0005 (0.0549%)
- Bid / Lots0.9105/ 10
- Ask / Lots1.0000/ 5
- Open / Previous Close0.9100 / 0.9100
- Day Range
- 52 Week Range
- Volume5,146
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AXLA |
|---|---|---|
| 09:32 ET | 490 | 0.91 |
| 09:57 ET | 300 | 1.01 |
| 10:15 ET | 500 | 1 |
| 10:18 ET | 116 | 0.93 |
| 10:29 ET | 120 | 0.921 |
| 11:21 ET | 1000 | 0.9605 |
| 12:10 ET | 300 | 0.921 |
| 12:12 ET | 458 | 0.921 |
| 12:46 ET | 984 | 1 |
| 01:38 ET | 105 | 0.9105 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Axcella Health Inc | 2.7M | 0.0x | --- |
Zyversa Therapeutics Inc | 2.7M | 0.0x | --- |
Innovation Pharmaceuticals Inc | 2.7M | -1.1x | --- |
Panbela Therapeutics Inc | 2.6M | 0.0x | --- |
Phio Pharmaceuticals Corp | 2.7M | -0.2x | --- |
Allarity Therapeutics Inc | 2.6M | 0.0x | --- |
Company Information
Axcella Health Inc. is a clinical-stage biotechnology company. The Company is focused on a new approach to treat complex diseases using compositions of endogenous metabolic modulators (EMMs). Its product candidates are comprised of multiple EMMs that are engineered in distinct combinations and ratios with simultaneously impacting multiple biological pathways. Its pipeline includes lead therapeutic candidates for the treatment of Long COVID (also known as Post-COVID-19 Condition and Post-Acute Sequelae of COVID-19 (PASC)) associated fatigue, and the treatment of non-alcoholic steatohepatitis (NASH). AXA1665 is a product candidate for the reduction in risk of Overt Hepatic Encephalopathy (OHE) recurrence in adult patients with liver cirrhosis. AXA1125 is also being developed as a product candidate for the treatment of Long COVID. AXA1125 is an oral product candidate for the treatment of NASH. AXA1125 is an oral product candidate that contains six amino acids and derivatives.
Contact Information
- Headquarters
- 840 Memorial DrCAMBRIDGE, MA, United States 02139-3789
- Phone
- 617-868-0949
- Fax
- 617-441-6243
Executives
- President, Principal Executive Officer, Principal Financial Officer, Principal Accounting Officer, Treasurer, Company Secretary, Director
- Craig Jalbert
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.7M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 2.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.58 |
EPS | $-19.12 |
Book Value | $1.41 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
